Integer Holdings Corp

ITGR

Equity

ISIN null / Valor 33080752

New York Stock Exchange, Inc (2025-12-26)

USD 78.88+0.22%

Integer Holdings Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Integer Holdings Corp is a leading medical device technology company that designs and manufactures a wide range of products, including catheters, guidewires, implantable ports, neuromodulation devices, and pacemaker batteries. With expertise in medical device development and battery design, Integer serves various markets, providing innovative solutions to medical device OEMs. The company's brands, such as Greatbatch Medical® and Lake Region Medical®, have a strong reputation for delivering high-quality products. With a history of industry-changing innovations and manufacturing excellence, Integer continues to be a trusted partner in the medical device industry, offering expertise in cardiac rhythm, cardio and vascular health, neuromodulation, and portable power solutions.

Summarized from source with an LLMView SourceSector: Finance

Sales

3Q25 sales were $468 million, an 8% increase versus 3Q24, with organic growth of 7%.

GAAP vs. Non‑GAAP Profitability

GAAP operating income decreased $2 million to $56 million (‑3%), while non‑GAAP adjusted operating income rose $10 million to $86 million (+14%).

Net Income and EPS

GAAP income from continuing operations increased to $40 million (+9%), and GAAP diluted EPS was $1.11 (+10%). Non‑GAAP adjusted net income increased to $63 million (+27%) and adjusted EPS was $1.79 (+25%).

EBITDA and Cashflow

Adjusted EBITDA increased 11% to $106 million. Full‑year 2025 adjusted EBITDA guidance is $398–$404 million. Projected 2025 cash flow from operations (GAAP) is $230–$240 million.

Balance Sheet and Leverage

Total debt rose $204 million year‑to‑date to $1.194 billion (Non‑GAAP net total debt $1.158 billion), primarily to finance acquisitions and costs tied to the 2030 convertible note offering; leverage was 3.0x adjusted EBITDA as of September 26, 2025.

Product Line Performance

Cardio & Vascular sales +15% (new product ramps and acquisitions); Cardiac Rhythm Management & Neuromodulation +2% (emerging neuromodulation PMA customers); Other Markets ‑16% (planned exit from portable medical products).

2025 Outlook

Updated 2025 guidance: reported sales $1,840–$1,854 million (7–8% growth); GAAP operating income $220–$226 million; adjusted operating income $319–$325 million (+12–14%); adjusted EPS $6.29–$6.43 (up ~19–21%).

Preliminary 2026–2027 Outlook

Preliminary 2026 outlook: reported sales down 2% to up 2%, organic sales flat to up 4%, adjusted operating income down 5% to up 4% and adjusted EPS down 6% to up 5% (vs. 2025). 2027 target: return to organic growth ~200 basis points above market.

Management Commentary

CEO Joseph Dziedzic highlighted strong quarter-to-quarter adjusted growth and said select headwinds are expected in 2026, but the company expects a return to above‑market organic growth in 2027 driven by its product pipeline.

Summarized from source with an LLMView Source

Key figures

-41.9%1Y

16.2%3Y

-3.36%5Y

Performance

48.7%1Y

37.6%3Y

36.3%5Y

Volatility